TSX · BLCO.TO
Bausch + Lomb Corporation
CA$28.75+CA$0.19 (+0.67%)
Bausch + Lomb Corporation’s quoted price sits in the upper half of its reported 52-week range, 3.3% below the high.
Loading market information…
OTC · ELIXF · USD
Stock price, earnings
Quote as of Oct 28, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Elixxer Ltd.’s quoted price sits in the lower half of its reported 52-week range, 58.12% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Elixxer Ltd.’s next earnings report is currently expected on Nov 26, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Elixxer Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Elixxer Ltd. operates as an investment company specifically focused on the cannabis industry. This firm strategically deploys capital into fully licensed businesses engaged in the cultivation, production, and sale of medicinal and specialized cannabis, as well as cannabis-derived products, predominantly for the pharmaceutical sector. Its investment reach extends across Canada, Australia, Italy, Jamaica, and Switzerland. Founded in 2004, the Montreal, Canada-based company adopted its current name, Elixxer Ltd., in August 2019, having previously been known as LGC Capital Ltd.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:05 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CA$28.75+CA$0.19 (+0.67%)
Bausch + Lomb Corporation’s quoted price sits in the upper half of its reported 52-week range, 3.3% below the high.
CA$33.67+CA$0.85 (+2.59%)
Apotex Health Corp.’s quoted price sits in the upper half of its reported 52-week range, 16.2% below the high.
CA$0.25+CA$0.02 (+6.52%)
Vext Science, Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.75% below the high.
$0.26-$0.00 (-0.11%)
C21 Investments Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.71% below the high.
$0.07$0.00 (0.0%)
Atlas Energy Corp.’s quoted price sits in the lower half of its reported 52-week range, 56.66% below the high.
$0.05$0.00 (0.0%)
MariMed Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.88% below the high.
CA$0.18-CA$0.01 (-5.26%)
1CM Inc.’s quoted price sits in the lower half of its reported 52-week range, 64.0% below the high.
$0.00$0.00 (0.0%)
BellRock Brands Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
